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This study looked at the thermodynamics of ligand binding to the Retinoid X 
Receptor (RXR) and the formation of the RXR auto-repressive tetramer.  Often called 
the “Master Coordinator” RXR is a required partner for activation of class II nuclear 
receptors. The first part used isothermal titration calorimetry (ITC) and site-directed 
mutagenesis to isolate and characterize the binding of a set of chemically diverse 
ligands to the RXR ligand binding domain.   
It was found that a molecule’s shape and flexibility play a crucial role in 
determining a ligand’s preference for the active or inactive form of RXR. These data 
showed that many RXR ligands appear to bind in a much stronger manner than was 
previously suggested by gene activation studies performed in cell culture.  Furthermore it 
was shown that the shape of the potential ligand, whether it is bent or straight, as well as 
the amount of available molecular flexibility determine which RXR form a ligand will 
preferentially bind to 
The second part of the study used ITC and native-PAGE electrophoresis to 
model the formation and dissociation of the RXR tetramer.  The initial model under 
consideration was a three stage model of monomer – dimer-tetramer equilibrium.  
However, non-linear curve fitting analysis of the proposed model to experimental data 
showed that RXR tetramer dissociation is much more exothermic than the model 
predicted.  This led to a proposed more complex model for the tetramer formation which 
addresses the larger than expect energy release.
iii 
 
A THERMODYNAMIC MODEL OF RXR SELF-ASSOCIATION AND LIGAND BINDING 
 
by 
 
James Patrick Healy 
 
 
A Dissertation Submitted to 
the Faculty of The Graduate School at 
The University of North Carolina at Greensboro 
in Partial Fulfillment 
of the Requirements for the Degree 
 Doctor of Philosophy 
 
 
Greensboro 
2014 
 
 
     
 
    Approved by 
    _____________________________ 
    Committee Co-Chair 
    _____________________________ 
                              Committee Co-Chair
 
 
 
 
ii 
 
APPROVAL PAGE 
 
 
This dissertation written by James Patrick Healy has been approved by the 
following committee of the Faculty of The Graduate School at The University of North 
Carolina at Greensboro. 
 
 
 
Committee Co-Chair_____________________________________ 
                                      _______________________________________ 
 
Committee Members_____________________________________ 
                                     ______________________________________ 
 
 
 
 
 
____________________________ 
Date of Acceptance by Committee 
_________________________ 
Date of Final Oral Examination 
 
 
 
 
iii 
 
TABLE OF CONTENTS 
 
Page 
 
CHAPTER 
 
 I. SPECIFIC AIMS AND HYPOTHESES ..................................................... 1 
 
 Specific Aim 1 ................................................................................. 1 
 Specific Aim 2 ................................................................................. 2 
 
 II. BACKGROUND AND SIGNIFICANCE .................................................... 4 
 
 Background ..................................................................................... 4 
 Tetramer Structure .......................................................................... 9 
 Homodimer Structure .................................................................... 10 
 RXR Ligand Binding Pocket. ......................................................... 10 
 
 III. RESEARCH DESIGN AND METHODOLOGY....................................... 16 
 
 Expression and Purification of Recombinant Protein .................... 16 
 Site Directed Mutagenesis ............................................................ 17 
 Native PAGE and SDS-PAGE Electrophoresis and  
 Western Blot Analysis ............................................................... 17 
 Isothermal Titration Calorimetry .................................................... 18 
 Ligand Binding Analysis ................................................................ 24 
 Modeling the RXR-LBD Tetramer Formation ............................... .29 
 
 IV. DISCUSSION AND CONCLUSIONS ..................................................... 37 
 
 Ligand Binding Study .................................................................... 37 
 Tetramer Dissociation Modeling .................................................... 39 
 Future Directions ........................................................................... 43 
 
WORKS CITED .................................................................................................. 44 
 
APPENDIX A. DERIVATIONS ............................................................................ 50 
 
APPENDIX B. POOLED STANDARD DEVIATION ............................................ 54 
 
APPENDIX C. ORIGIN FITTING PROGRAM ..................................................... 55 
 
 
 
iv 
 
APPENDIX D. NATIVE PAGE DATA ................................................................. 60 
 
APPENDIX E. ITC THERMOGRAMS ................................................................. 63 
  
1 
 
CHAPTER I 
SPECIFIC AIMS AND HYPOTHESES 
 
 
The nuclear hormone receptor (NR) family of proteins plays critical roles in a 
variety of cellular signaling pathways within the human body1.  Through their binding of a 
“drug-like” ligand molecule, NRs regulate the expression of a wide number of gene 
networks in the cell2.  Among NRs, the Retinoid X Receptor (RXR) is particularly 
important.  Often referred to as the “Master Coordinator”, RXR is a required heterodimer 
for an entire class of NRs3 
  The ligand binding domain (LBD) of RXR has a mechanism of self-regulation and 
activation through the formation of apo-tetramers that dissociate upon ligand binding and 
form activated homo- or heterodimers4.  This pathway is not completely understood, 
particularly because there are few direct biophysical measurements of the kinetic and 
thermodynamic parameters of these pathways.  This study makes use of isothermal 
titration calorimetry (ITC) in conjunction with normal RXR LBD and mutant RXR LBD 
versions produced by site directed mutagenesis to isolate the events associated with 
RXR multimerization and obtain direct biophysical measurements of this mechanism. 
Specific Aim 1: To obtain specific and direct biophysical measurements of the 
interactions of different ligands with RXR and observe the ligand effects on the relative 
amounts of different RXR complexes. 
The current scientific literature contains a wealth of data on RXR-ligand 
interactions from in-vitro and cell signaling assays.5 6 7    Since ITC directly measures the 
energies of interaction between two molecular species, information on interactions that 
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cannot be studied with in-cell assays such as ligand binding can be obtained.   ITC was 
used to characterize the interactions of RXR with different known ligands including the 
fatty acids, docosahexanoic acid (DHA)and phytanic acid which have been hypothesized 
to be endogenous ligands for RXR8.  Also tested was 9-cis-retinoic acid (9cisRA), the 
classical RXR ligand9 and Dantron, an RXR antagonist which stabilizes the inactive 
tetramer of RXR10.   
Fatty acids such as DHA and phytanic acid, should show the ability to interact 
with RXR in both tetrameric and dimeric forms. This xpectation is based upon evidence 
that the RXR ligand binding pocket adopts a linear “I-shaped” conformation while in its 
inactive state and undergoes a conformational shift to a bent “L-shaped” conformation in 
its active ligand bound shape11.  Both DHA and phytanic acid are flexible fatty acid 
molecules which should be able to match either conformation of RXR.  This is unlike 
9cisRA and Dantron, which are rigid molecules and are predicted to show strong 
interactions with RXR in only one form. 
Furthermore with data from several different ligands, structural features which 
predispose a molecule to dissociate or stabilize different RXR multimers can be begin to 
be identified.  This could allow for development of potential therapeutics which can 
interact with and interrupt the regulation of RXR complex formation by ligands, whether 
natural or artificial.   
Specific Aim 2: To develop a thermodynamic model of RXR complex formation 
and dissociation- using Isothermal Titration Calorimetry (ITC). 
By using thermodynamic data obtained from ITC, a proposed model of RXR 
multimer formation and dissociation will be explored.  In this study the effects of different 
mutant RXR proteins will be measured with ITC and the energies associated with the 
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formation of each species will be measured. Site directed mutations of RXR will be used 
to test protein-protein interactions of RXR mutants that predictably disrupt the normal 
formation of monomers, dimers, and tetramers. 
It was hypothesized that the likely equilibrium system to represent the distribution 
and formation of each RXR-LBD multimeric states could be written as below 
 
Equation 1)  4 2 ⇔
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CHAPTER II 
BACKGROUND AND SIGNIFICANCE 
 
Background:  Nuclear Receptors (NRs) are a family of transcription factors that 
reside in the cytoplasm and nucleus of cells1.  NRs are defined by the presence of a 
DNA binding domain that contains two cysteine-cysteine zinc fingers separated by a 
linker region.  This domain is responsible for direct interaction with specific DNA 
sequences.  NRs regulate a variety of developmental, homeostatic, and metabolic 
functions at the cellular level12.  Typically a NR acts by binding a small lipophilic 
molecule such as a steroid, vitamin, fatty acid or other dietary metabolite13. 
With the widespread interactions of the nuclear receptor superfamily with almost 
all aspects of human physiology, the role of these receptors in many human diseases, 
and their importance as therapeutic targets for pharmaceuticals, it is obvious that the 
understanding of them has implications, not only for human biology but also for the 
understanding and development of new drug treatments2. 
In general, ligand binding, causes the receptor's conformation to change from an 
inactive to an active conformation. This activation often results in the homo- or 
heterodimerization of the NR and binding of the now-activated NR to specific sequences 
of DNA in the genome known as response elements (REs)14.  Once bound to its specific 
RE the receptor begins recruitment of other transcription or repression factors, thereby 
causing the up-regulation or down-regulation of a target gene’s expression15.  These 
activating ligands are often low molecular weight, hydrophobic molecules.  These “drug-
like” qualities of the NR’s ligand molecules  along with their far-reaching influence into all 
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parts of human physiology have made them attractive targets for pharmaceutical 
development16.  
The NR family is roughly divided into four classes based on their mechanisms of 
activation and binding to response elements (REs)1.  REs are short sequences 
of DNA found within the promoter region of a gene which have the ability to bind 
specific transcription factors in order to regulate transcription of the associated gene. 
Type 1 NR’s (Steroid Receptors) typically bind as ligand bound homodimers to hormone 
response elements (HREs) consisting of two half-sites that are separated by a variable 
length of DNA.  The second half-site contains a sequence inverted from the first site (an 
inverted repeat).  Type II NR’s (RXR Heterodimers) function as heterodimers with RXR 
as the dimerization partner and function in a ligand dependent manner.  These dimeric 
complexes usually bind to direct repeat response elements in contrast to type I NR’s.  In 
the absence of ligand, type II nuclear receptors are often found in complex with 
corepressor proteins. Binding of ligand to the NR causes dissociation of the co-repressor 
and recruitment of coactivator proteins.  Type III (Dimeric Orphan Receptors) NRs bind 
to DNA as homodimers, similar to type I receptors. However, type III NR’s bind to direct 
repeat HREs unlike type I NRs which bind to inverted repeat HREs. Like other NR 
classes Type IV NR’s (Monomeric or Tethered Receptors) can bind either as monomers 
or dimers.  Unlike other NRs however, only a single DNA binding domain (DBD) of the 
receptor binds to a single half site of an HRE regardless of any dimerization the receptor 
may undergo17. 
The sub-family of nuclear receptors known as class II or RXR heterodimer 
receptors contains the Vitamin D Receptor (VDR), Peroxisome Proliferators-Activated 
Receptors (PPARs), Farnesoid X Receptor (FXR) and the Thyroid Hormone Receptor 
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(TR) among others.  Members of this subfamily require the Retinoic X Receptor (RXR) 
as a dimeric partner to regulate transcriptional activity.  This central regulatory position 
has led to RXR being described as the “master coordinator”3. 
RXR holds a unique position in the NR family for more than its role as a “Master 
Coordinator.”  In addition to its heterodimeric capability, it is active as a homodimer and 
it adopts a scheme of for self-inactivation/regulation not found in other members of the 
family.  Although the receptor only contains a single ligand binding site (two in the 
homodimer), studies have shown that the heterodimeric and homodimeric transcriptional 
activity may fulfill separate regulatory functions6.  Across all four classes, NRs share a 
modular construction consisting of several shared domains (see Figure 1). The N-
terminal or A/B domain is highly variable in sequence among the nuclear receptors. The 
C domain is a highly conserved domain containing the DNA binding domain (DBD) of the 
NR.  The DBD consists of two zinc fingers responsible for binding to the hormone 
response elements (HREs) in order to modulate expression of their associated genes. 
The cysteine-cysteine zinc fingers within the DBD are the defining structural domain for 
most members of the nuclear receptor superfamily.  The D domain is a flexible “hinge” 
domain which connects the DBD with the LBD. Though the D domain’s function is not 
completely understood some have postulated a role in regulation of DNA binding and 
subcellular distribution in some NRs.   
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Figure 1. Arrangement of a Typical Nuclear Receptor Domain’s 
This figure shows the typical layout of the different domains of a nuclear receptor with 
important features identified within those domains.  16,15 
 
 
The E region is the ligand binding domain (LBD).   While the LBD generally 
shows moderate amino acid sequence conservation, its secondary structure is highly 
conserved among different NRs. The common structural motif of the LBD is what is 
generally referenced to as an alpha helical sandwich.  The LBD also generally contains 
the dimerization interface of the receptor.  
NRs contain two separate activation domains for the recruitment of cofactors and 
repressor proteins that regulate gene expression.  These are called activation function 1 
(AF-1)  and activation function two (AF-2)16 .  The AF-2 requires the presence of a bound  
ligand for activation and transcriptional activity. In contrast the AF-1 domain, located in 
the A/B domain, shows basal transcriptional activation, though it is normally very weak, 
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but sometimes synergizes with AF-2 to produce stronger up-regulation of gene 
expression upon ligand binding. 
Several crystals structures exist in the literature of RXR, both full length RXR and 
of the RXR-LBD only.  A few are of particular interest in terms of this study.  Bourguet et 
al. published a structure of the RXR-LBD (1LBD) which highlights the movement of the 
AF-2 helix upon ligand binding (See figure 2)18.   Published crystal structures reveal that 
the LBD contains 13 α-helices and two β-strands folded into a helical “sandwich” which 
form a hydrophobic ligand-binding pocket. 
 
  
Figure 2. Superimposition of crystal structures of apo-RXR-LBD (blue) and ligand bound 
RXR-LBD (red) 24 
 
 
In the apo-RXR structure, the AF-2 helix extends downward from the α-helical 
“sandwich “and provides an entry point for the ligand. Agonist-bound structures have the 
AF-2 helix packed against the body of the receptor, forming an essential part of the 
charge clamp for recruitment of coactivator proteins18.  
Two other structures of importance to this study are 1MV911 and 1G5Y18 which 
show RXR bound to DHA and 9cisRA respectively.  These structures will be discussed 
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later in more detail later but are important in the context of this study as they show the 
conformational difference in the ligand binding pocket in the tetrameric and dimeric 
forms. 
Tetramer Structure:  In the absence of ligand, RXR exists as a homotetramer4.  
These tetramers retain DNA binding capacity but lack the ability to recruit transcriptional 
cofactors.  Since RXR monomers retain their homodimerization ability regardless of 
ligand binding, previous study has shown that this tetrameric form performs an additional 
autorepressive function beyond binding to and blocking expression of RXR controlled 
response elements.  The sequestering of RXR monomers into tetramers apparently 
limits availability of the RXR monomer for heterodimerization19. 
The RXR tetramer is a compact, disc-shaped tetramer formed of four RXR LBD 
monomers.  H10 of each monomer forms the main part of each’s dimer interface.  Each 
monomer has three main areas which make up the tetramer interface: the H3/H3 
interface, the H11/H11 interface, and the interface between the H12 and coactivator 
binding site.  The main portion of the tetramer interface is formed by the H11 helix of 
each monomer in the upper dimer being packed against the corresponding H11 helix in 
the lower dimer.   The AF-2 helix follows H11, protruding outward from each LBD into 
the coactivator binding site of the corresponding monomer in the lower dimer.  The RXR 
tetramer structure is an autorepressed complex, assembled from two symmetric dimers 
that cross-repress each other through the extended AF-2 helices.  The H3/H3 interface 
is made up of the amino-terminal end of H3 from the upper dimer monomer and the 
amino-terminal end of H3 of the adjacent monomer in the lower dimer11.   
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Homodimer Structure:  The RXR homodimer was described by Gampeet al as 
“Butterfly shaped, with two symmetric monomers rotated 180° relative to each other 
around the twofold axis11.”  Residues from H7, H9, as well as the loop connecting H8 
and H9 contribute most of the charged interactions including the formation of 
complementary hydrogen bonds.  The majority of the dimer interface is comprised of 
non-polar interactions resulting from a paired-coil structure of H10.  Interestingly, several 
polar interactions in the PPAR/RXR heterodimer are missing in the RXR homodimer 
interface20.  Some combination of these may also be missing in other RXR heterodimers 
although these have not been confirmed21. If so these could play in role in the observed 
preference for certain heterodimer formation versus others or homodimer formation. 
RXR Ligand Binding Pocket:  When discussing the ligand binding pocket of 
RXR s an orientation where the “top” of the monomer in question is defined as the 
portion exposed to solvent and directly opposite the AF-2 helix will be used.  With this 
orientation the ligand binding pocket of RXR can be described as follows: H5 forms the 
top with H11 on the bottom, H3 on the right with H7 and H10 on the left and the β-hairpin 
on the back. The pocket is accessible to the solvent on the left side between H11 and 
H322.   
Ligand binding to the RXR LBD, induces a change in the conformation of the AF-
2 helix.  This releases corepressor proteins and causes formation of the charge clamp 
that is capable of recruiting coactivator complexes.  These ligand binding events begin a 
cascade which leads to activation of the target gene and subsequent various 
physiological changes desired23. 
Previous crystallographic studies have shown that the RXR ligand binding 
domain (LBD) adopts two unique conformations.  In monomeric or dimeric form the LBD 
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conformation presents a "L-shaped" ligand binding pocket.  This is the form responsible 
for gene activation via homo- or heterodimerization.  The second form is only found 
within the autorepressive homotetrameric RXR form.  In this the conformation the LBD 
presents a linear "I-shaped" binding pocket11.  This property offers the possibility of 
approaching each of these RXR states as separate pharmaceutical targets.  Several 
published studies have already begun to make strides for exploring the distinct 
pharmaceutical properties of these states.24 25    Molecular docking simulations have 
been used to begin designing ligands to  activate RXR homo- and heterodimeric 
functions selectively.  RXR self-regulation presents unique opportunities for drug 
development26. 
The search for the endogenous RXR ligand has seen much debate and study 
since the original identification of the receptor.  In 1992, Heyman, Mangelsdorfet al. 
undertook a study to answer this question.  Mangelsdorf et al. hypothesized that since 
RXR and the retinoic acid receptor (RAR) share similar structural motifs,  RXR  
conceivably binds an isoform of all-trans-retinoic acid, the endogenous ligand of RAR.  
Using from extracts of mouse livers they found via, HPLC and GC/MS that RXR bound 
9-cis-retinoic acid with a high affinity9. At the same time Levin et al showed in a study 
with COS-1 cells expressing RXR that 9-cis-RA also bound and activated RXR27.  Based 
on these studies, 9-cis-retinoic acid was generally accepted as the naturally occurring,  
endogenous ligand for RXR.  
Several further studies in the early 90’s ((Yu et al., 1991; Durand et al., 1992; 
Hallenbeck et al., 1992; Leid et al., 1992;Zhang et al., 1993) showed that RXR is 
activated in cell culture by 9cisRA.28 29 30 23   Further they showed that once activated 
RXR can bind to specific DNA response elements and regulate transcription as a 
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homodimer.  The 1991 Yu study first established the existence of RXRβ, and looked at 
bothRXRα and – β as heterodimeric partners for RAR using transfected CV1 cells and 
monitoring luciferase activity to measure 9cisRA activation of both isoforms for RXR. 
Durand et al. in a 1992 study used a series of CAT (Chloramphenicol Acetyl 
Transferase) assays to establish that RXR-RAR heterodimers are responsible for 
cellular retinoic acid-binding protein II (CRABPII) promoter transactivation.  Specifically, 
they found that the interaction is RXR-RAR specific and not controlled by RAR alone.  
They identified the pair as working through the DR1 and DR2 direct repeat motifs.  Both 
the Zhang and Hallenbeck studies showed that the Thyroid Hormone Receptor also 
requires heterodimerization for gene activation. 
Later, Ulven et al. (2001) investigated the distribution of retinoid along the 
developing spinal cord of mouse embryos by means of ultrasensitive HPLC/MS. 
Although RXR was present and the presence of all-trans-retinoic acid was easily 
observable, no 9-cis-retinoic acid could be detected.  Urbach and Rando, observed that  
all-trans-retinoic acid shows spontaneous (non-enzymatic) isomerization to 9-cis- 
retinoic acid31.  The presence of 1% BSA and SDS, without any source of enzymatic 
activity, was found to transform all-trans-retinoic acid into 9-cis-retinoic acid to levels of 
approximately 15% isomerization at equilibrium. This finding suggests that the earlier 
detection of 9-cis-retinoic acid in animal tissues could be the result of spontaneous 
conversion of the all-trans-retinoic acid into the 9-cis-form. 
A 2006 genetic study by Chambon showed that for at least one system 9-cis-RA 
can be definitively excluded as an endogenous RXR ligand32.  Newborn mouse skin cells 
produce a characteristic protein called corneodesmosin packaged in small organelles 
called lamellar granules. The authors found that lamellar granules required the presence 
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of RAR/RXR heterodimer (with RAR unliganded) and the presence of PPAR/RXR where 
PPAR is the peroxisome proliferated activated receptor.  The RXR in the heterodimer 
PPAR/RXR is liganded.   Furthermore, topical treatments of wild-type newborn mouse 
skin with 40 nM all-trans-retinoic acid caused the loss of lamellar granules which are 
seen in RAR knockout cells.  The authors proposed two hypotheses.  Firstly, two 
signaling pathways are needed for lamellar granule formation, requiring the nuclear 
receptor heterodimers RAR /RXR (with the RAR unliganded) and PPAR/RXR(with the 
RXR bound to a ligand).   If 9-cis-retinoic acid were a ligand of the RXR , then the 9-cis-
retinoic acid present in vivo would also bind to RAR,since RAR is not stereo-selective 
between 9-cis-retinoic acid or all-trans-retinoic acid.  Since granule formation requires 
unliganded RAR, clearly 9cisRA cannot be an endogenous ligand for RXR in newborn 
mouse skin cells.       
What then is the natural ligand for RXR?  Multiple sources have shown RXR to 
be activated by a variety of long chain fatty acids, primarily phytanic acid and 
docosahexaenonic acid (DHA).33-35   Both bind to RXR at low micromolar concentrations 
(66µM for DHA and 2.3µM for phytanic acid) and are naturally occurring in cells.  Also 
both have been shown to activate pathways in which RXR plays a regulatory role in 
proteomic studies. 36 37 35 38 39 40   DHA is particularly promising as it has been shown to 
be a natural RXR ligand in mouse brain tissue33. 
The current work makes extensive use of isothermal titration calorimetry, or ITC, 
to study the interactions of RXR monomer both with themselves and ligand molecules.  
An isothermal titration calorimeter consists of two identical cells made of a thermal 
conducting and chemically inert material, surrounded by an adiabatic water jacket41. 
Sensitive thermocouple circuits are used to detect temperature differences between the 
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reference cell (filled with buffer or water) and the sample cell containing the 
macromolecule. Prior to addition of ligand, a constant power is applied to the reference 
cell. This directs a feedback circuit, activating a heater located on the sample cell. 
During the experiment, ligand is titrated into the sample cell in precisely known aliquots, 
causing heat to be either taken up or released (depending on the interaction under 
investigation). Measurements then consist of the time-dependent input of power required 
to keep the reference and sample cells isothermal. 
In an exothermic interaction, the temperature in the sample cell increases as the 
interaction occurs. This causes the feedback power to the sample cell to be decreased 
in order to maintain an equal temperature between the two cells. In an endothermic 
interaction, the opposite occurs; the temperature of the sample cell decreases, thus 
causing more power to be applied via the feedback circuit in order to maintain isothermal 
conditions 
Measurements are plotted as the power needed to maintain the reference and 
the sample cell at an identical temperature over time. This causes the resulting raw 
experimental data to consist of a series of spikes of heat flow (measured as changes in 
power), with every spike corresponding to one injection. By integrating these injection 
spikes with respect to time, the total heat exchanged per injection can be determined. 
Thus by looking at these integrated heats as function of the molar ratio, binding affinity 
(k), change in enthalpy (∆H) and change in entropy (∆S). 
Direct biophysical measurements of ligand interactions with wild-type and 
mutated forms of the RXR LBD, can give information concerning the extent to which 
molecular binding events are ΔS or ΔH driven and how favorable the overall free energy 
change will be.   Eventually, this methodology could allow the rational design of RXR 
15 
 
ligands based on features in addition to strong binding affinity.  These measurements 
can help to provide a framework in which a medicinal chemist can design a molecule to 
target a specific RXR multimer and then test that molecule, measure ligand/RXR affinity 
and detect the energy changes brought on by binding (ΔH, ΔS).   Furthermore, by 
careful analysis and control of macromolecule/ligand molar ratios the presence of 
multiple sequentially binding sites can be detected and coopertivity either positive or 
negative which might exist between them determined. 
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CHAPTER III 
RESEARCH DESIGN AND METHODOLOGY 
 
Expression and Purification of Recombinant Protein: RXR encoding 
expression vectors for our study were purchased from DNA 2.0 (Menlo Park, CA).  The 
first is RXR-EF which contains the E and F regions only.  The vectors include a promoter 
for the T7 RNA polymerase and attach a C-terminal 6-histidine (6His) affinity tag.  All 
references to wt-hRXRα will refer to this RXR-EF domain clone. The wt-hRXRα 
expression vector was transformed into E. coli BL21-DE3 cells.  Protein purification was 
performed by included methodology on His-Trap affinity purification columns.  
Crude extract  and samples of each stage of column elution were saved and 
checked by SDS-PAGE and presence of hRXAα-LBD was confirmed by Western Blot 
analysis (Figure 3).  Eluted protein was concentrated and elution buffer exchanged with 
assay buffer using Pierce Concentrators 20k MWCO (Thermo Scientific).  Final 
concentrations were determined by Bradford assay on a NanoDrop 2000 
Figure 3. Western Blot Analysis of purified protein 
showing presence of hRXRα 
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Spectrophotometer.   Final protein preparations were used immediately in assays to 
reduce the possibility of instability of the recombinant LBD. 
Site Directed Mutagenesis:  Site-specific mutants of the RXR-LBD were 
produced using the Quik-Change II XL Site Directed Mutagenesis kit.  The 
manufacturer's instructions were followed.  Primers for site directed mutagenesis (SDM) 
were designed by hand to give appropriate Tm and %GC content and then ordered from 
Integrated DNA Technologies (IDT).   For this study, two mutants were produced, F315A 
and R318A.  (See Figure 4)  .   R318A and F315A have been shown previously to 
prevent dissociation or formation of the inactive tetramer, respectively.21 18    
Both mutated plasmids were transformed into bacterial hosts and purified in the 
same manner as previously described for wt-RXR.  Purified mutant RXR forms were 
verified by western blot and non-denaturing PAGE gels to verify the intended effect of 
the mutations.  Both mutations were verified by DNA sequencing of the clone encoding 
the mutant protein form 
Native PAGE and SDS-PAGE Electrophoresis and Western Blot Analysis:  
Purified proteins samples were analyzed under non-denaturing and denaturing PAGE 
electrophoresis.  For western blotting the initial SDS PAGE was performed on 10% mini 
TGX gels purchased from Bio-Rad.  Following this, the samples were transferred using 
the Trans Transfer Turbo blot kits from Bio-Rad.  Blotted membranes were treated with a 
RXR specific primary antibody (RXR C-20 rabbit polyclonal, purchased from Santa Cruz 
Biotech).  After this, they were developed with aImmunostar AP secondary antibody and 
substrate kit (BioRad).  For Native PAGE, precast Tris-glycine gels were purchased from 
Bio-Rad with percentages from 7.5% to 10%.  Electrophoresis was performed at a pH of 
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8.0 and at a voltage of 200V and a current never exceeding 45mA. Gels were stained 
with a Coomassie Blue stain. 
Isothermal Titration Calorimetry: ITC experiments were performed using a 
ITC200microcalorimeter (Microcal,Inc). Purified RXR LBD was dialyzed against sample 
buffers to be used in the ITC assays.  A concentrated solution of purified and dialyzed 
RXR-LBD in assay buffer was loaded into the injection syringe while the sample cell was 
filled with dialyzed assay buffer.  If applicable for the experiment, the ligand to be studied 
was added to the sample cell buffer to the desired concentration.  Both sample and 
reference cells were heated to 28 degrees Celsius.  A number of injections where made, 
with the first being a 0.5µL “throwaway” injection while the final 15 - 20 injections were 
each between 1.0 and 1.5µL. 
In order to avoid large dilution heats which could mask the heat changes of any 
interactions, the concentration of organic solvent in the protein solutions must be 
matched to the concentration in the ligand solution.  Since concentrations of more than 
1%-2% DMSO will inhibit the activity of our protein, the maximum concentration of ligand 
was between 50-75µM depending on the ligand. 
Two sets of ITC assay’s were performed for each RXR-ligand assay.  Both 
involved making injections of concentrated solutions of RXR into the sample cell.  In one 
set the cell contained the ligand to be studied in appropriate buffer and organic solvent 
needed to ensure solubility.  The second was identical to the first except that no ligand 
was present in the sample cell, though care was taken to ensure that the buffer was 
identical except for the absence of ligand. 
The first goal of the study was to isolate and test the effect of specific point 
mutations in the RXR LBD to isolate the different oligomeric states adopted by RXR.  
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The R318A mutant prevents dissociation of the RXR tetramers upon ligand binding and 
the, F315A mutant RXR inhibits tetramer formation. Where possible, each mutant was 
verified using visualization via native PAGE (Figure 4). 
In order to verify the multimeric states of RXR Native PAGE electrophoresis was 
used to monitor these states under non-denaturing conditions.   
As expected, wt-RXR was found to favor the tetrameric state although this equilibrium 
rapidly shifted to favor the dimeric form with increasing agonist concentration (DHA 1-
5uM) (See Fig. 4).  The antagonist Danthron did not dissociate the RXR tetramer even at 
Figure 4. Native PAGE Electrophoresis of RXR and 
RXR mutant forms 
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higher concentrations (5uM) (Figure 4b).  A similar effect was seen with the R318A 
mutant, where the tetramer fails to dissociate with increasing agonist concentration . 
The ITC system monitors the changes in power required by the heating units to 
keep the sample and reference cells isothermal during the injections as a plot of µcal/s 
vs total time elapsed.  Injections are spaced far enough apart that the baseline can 
return to equilibrium between injections.   
By integrating the area under each injection peak with respect to the current 
macromolecule concentration in the cell, total energy released (in µcals per mole) for 
each injection can be calculated.  This is the plot of integrated heat per mole of injectant 
vs. molar ratio of macromolecule to ligand as an ITC thermogram. 
 
Figure 5.  Ligands under investigation  
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Four different ligands of RXR-LBD  were tested (See Figure 5).  Three are known 
are agonists and one is an antagonist.  Two are fatty acids, docosahexsonic acid (DHA) 
and phytanic acid, both of which have been shown to activate RXR in cell culture 
assays32,29.  Also used in 9-cis-Retinoic acid (9cisRA) the classical RXR.  Finally, we will 
use Dantron, an RXR antagonist, shown to bind and stabilize the RXR inactive 
tetramer8.  All-trans-Retinoic acid was initially investigated as another antagonist for 
RXR24 as it shares affinity for the inactive tetramer with Danthron.  However, due to the 
instability of transRA and the readiness which with it will isomerize to 9cisRA in solution 
it was excluded from this study. 
Preliminary studies showed that RXR injections performed in the presence of 
ligand showed a much greater energy release per mole than the same injections 
performed without ligand present.  This increased energy release in the presence of 
ligand suggests that interactions between the RXR-LBD and ligand molecules are 
happening and are strong enough to detect with our methodology. 
However the thermogram is a composite of both inactive tetramer dissociation 
and ligand binding/active dimer formation.  In order to isolate the ligand binding events,   
the thermograms of RXR in the absence and presence of ligand were compared to each 
other. 
The total heat for the injections of RXR-LBD in the absence of a ligand can be 
expressed as follows, 
 
Equation 2)   qtot=qinactive 
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where the total heat is equal to the heat released from the dissociation of the inactive 
tetramer. 
However, when a ligand for RXR is present the equation for total heat released 
incorporates multiple terms as there are now two separate events happening with each 
injection:  dissociation of the inactive tetramer to reach equilibrium, binding of ligand, and 
formation of the active dimer.  Therefore the total heat released for each injection can be 
expressed as follows, 
 
Equation 3)   qtot=qinactive+qbind. 
Since heat released is an additive quantity and the ITC experimental protocols are 
identical between experiments, the thermogram from the ligand negative experiments 
can be subtracted from those of the ligand positive ones. (Fig 6)  This allows for isolation 
of the energy released unique to the ligand activation events and the ligand binding 
events. 
23 
 
      Figure 6.  Isolation of ligand binding energies 
A) Raw ITC trace with integrated heats below for titration of wt-RXR in the absence 
of ligand 
B) Raw ITC trace with integrated heats below for titration of wt-RXR in the presence 
of ligand (DHA) 
C) Superimposition of integrated heats of DHA (+) and DHA (-) experiments 
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Ligand Binding Analysis:  In measuring binding of potential ligand to RXR-LBD 
two assumptions were made: 
1. Any dissociation of the tetramer due to dilution at each injection happens 
immediately and before any interaction with the ligand. 
2. Each binding site on tetrameric and dimeric RXR-LBD is equally probable. 
Initial studies showed that titration of wt-RXR with known agonists DHA and 9-
cis-retinoic acid (9cisRA) generated a thermogram reflective of a model with two binding 
sites.  This two site binding model became apparent after the heats related to 
dissociation of tetrameric RXR due to dilution from the ligand binding thermograms were 
subtracted.  A sequential binding model often occurs in biological systems where the 
binding of a ligand to one site will be influenced by whether or not a ligand is bound to 
other sites.   
In a typical titration with two available sets of sites, the strongest binding of the 
two sites, whose heat change is H1, will titrate in the early injections while the weaker 
site, with heat change H2, will titrate in subsequent injections until both are saturated. 
After this point the heat change will drop to zero. 
Since our experiments are performed with ligand injected in the cell, the ligand 
will be in excess after the initial few injections.  This means that both sites will bind 
ligand with the heat change equaling that of H1 + H2. Once sufficient macromolecule 
has been added to interact with all of the ligand as the 2-to-1 complex, then further 
injections of the apo-macromolecule will result in some of the ligand being removed from 
the weaker site in the 2-to-1 complex so that it can bind to the stronger site on the newly-
injected macromolecule. The heat change for this second phase of the titration will then 
be H1 - H2. 
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The DHA binding isotherm (See Figure 7) for wt-RXR clearly showed two binding 
states. 
 
DHA showed a dissociation constant for K1 of 2.6nM, while its K2 value was 1.1µM.  
Thermodynamically, DHA shows a higher enthalpy in its first binding site than 9cisRA (-
3.88 vs -2.9 kcal/mol) while the changes in entropy where close (25.9 vs 23.3 
cal/mol/deg Cº).  In the R318A mutant the tetramer is prevented from dissociating upon 
ligand binding. The measured dissociation constant for binding of DHA drops 
significantly from 2.65nM to 98.4µM.  The change in enthalpy also drops significantly to -
1.65 kcal/mol.  The change in entropy value remains fairly consistent at 20.8 cal/mol/deg 
Cº. 
Figure 7. Subtracted thermograms of wt-hRXR and R318A and F315A titrations in 
the presence of DHA 
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In the F315A mutant the tetrameric conformation is prevented from forming 
regardless of whether or not an agonist is present.  The Kd is close to constant, while the 
enthalpy of dissociation increased from -1.439 to -2.44 kcal/mol.  The 9cisRA isotherm 
(see Figure 8) lacked two clearly distinguishable binding phases suggesting that K1<K2.   
 
The ITC data alone does not show two clear distinct binding phases.  However, 
when viewed in conjunction with our Native-PAGE data which showed the presence of 
both tetrameric and dimeric forms in the presence of 9cisRA along with the fact that the 
data was a poor fit for single binding site equilibrium, prompted us to hypothesize that 
wt-RXR does exhibitl two site binding.   
9cisRA showed an initial dissociation constant of 2.3µM for the tetrameric form of 
RXR while it showed a much stronger affinity for dimeric form (23.4nM).  The R318A 
 
Figure 8.  Subtracted thermograms of wt-hRXR and R318A and F315A titrations in 
the presence of 9-cis-Retinoic Acid 
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mutant showed the weakest affinity for 9cisRA with a dissociation constant of 16.7 µM 
while the F315A mutant had a higher affinity at 530nM 
The phytanic acid binding isotherm (See Figure 9) for wt-RXR clearly showed 
two phases where K1>K2 similar to DHA with two binding states as in DHA.   
 
 
Figure 9. Subtracted thermograms of wt-hRXR and R318A and F315A titrations in 
the presence of Phytanic Acid 
 
 
The ligand showed a dissociation constant for K1 of 1.35 nM, while its K2 value 
was 4.5µM.  Thermodynamically, it shows an enthalpy value of -7.34 kcal/mol in its first 
binding while the entropy value changes from 15.9 to 19.6 cal/mol/deg Cº.  In the R318A 
mutant the tetramer is prevented from dissociating upon ligand binding. This caused the 
dissociation constant for binding of phytanic acid to drop from 1.35nM to 4.3µM.  The 
enthalpy of dissociation also drops significantly to -1.861 kcal/mol.  The change in 
entropy value remains fairly consistent at 22.4 cal/mol/deg Cº. 
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In the F315A mutant the tetrameric conformation is prevented from forming 
regardless of whether or not an agonist is present.  The Kd is changes to 75.2µM, while 
the change in enthalpy decreased to -2.07 kcal/mol. 
Titration with a RXR antagonist, Dantron, does not show a two site model, 
instead fitting to a single site model with a 1:2 macromolecule to ligand stoichiometry.  
Danthron was found to have a dissociation constant of 11µM, while thermodynamically it 
was found to bind in a more ΔS driven manner, with a smaller contributions from ΔH.  
The R318A mutant showed an even stronger affinity for Dantron than the wild type while 
the F315A mutant showed a very weak low millimolar affinity (3.71mM). 
 
 
Figure 10. Subtracted thermograms of wt-hRXR and R318A and F315A titrations in 
the presence of DHA 
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Both DHA and PA showed indications of positive co-operativity between the binding 
sites in contrast to our earlier assumptions.  This will be discussed further in the next 
chapter. 
Modeling the RXR-LBD Tetramer Formation: The next portion of the study 
looked to establish a model for formation of the RXR-LBD tetramer and to define the 
formation and dissolution of the tetramer both by its kinetic and thermodynamic 
parameters.  Throughout this section reference is made to both total monomeric units 
present and monomers present.  It is important for clarity to distinguish between the two.  
When monomers are referred to only RXR-LBD’s existing in a momomeric state are 
meant.  In contrast total monomeric units refer to the amount of RXR-LBD monomers 
present in any multimeric state.  So a RXR tetramer would contribute 4 monomers to the 
total monomeric units present, for example.  For this dissertation total monomeric units 
will typically be referred to as a concentration in molarity, as indicated by the brackets 
around its symbol.   
As discussed earlier both previous studies4 and our own work have shown that 
RXR-LBD can exist in three multimeric states, a monomer, a dimer, and a tetramer.  It 
was hypothesized that the likely equilibriums system to represent the distribution and 
formation of each RXR-LBD multimeric states could be written as below 
 
Equation 4)   4[ ] 2[ ] ⇔ [ ] 
 
The above model was picked for our initial studies as it represents the simplest model 
for RXR multimerization.  While other models could be written which all contain more 
complex relationships there exists no evidence currently in the literature to support their 
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existence over the simpler, more streamlined system.  Using the above model we can 
then define the dissociation constants for each mulitmer: 
 
Equation 5.1)  = [ ]
[ ]
   Equation 5.2)  = [ ]
[ ]
 
 
With these definitions we can define the total equivalent concentration of RXR 
monomeric units ([M]T,i) within the ITC cell after any injection.  First we define the initial 
relationship between [M]T,i  and each dimeric form: 
 
Equation 6)  [ ] , = [ ] + 2[ ] + 4[ ]  
 
Next the above definitions are rewritten in Equation 4 in terms of the dimer and tetramer 
concentrations only, since these two values are readily measurable from Native-PAGE 
experiments: 
 
Equation 7)  [ ] , = [ ] + 2 [ ] + 4[ ] 
 
For further derivations see appendix 1. 
With ITC we measure the heat energy gained or released per injection (qi) which 
can be defined as a function of the concentration of all monomeric units ([M]Tot,i ) added 
to the sample cell with each injection : 
 
Equation 8)  = ([ ] , )  
 
Since this analysis requires the change in heat due to the aggregate macromolecules 
injected only and not any heat released to dissociation or association of already present 
macromolecules we can define the net heat released with each injection as below.  The 
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net heat change per injection is the total heat content of multimer units contained in the 
injection volume minus the difference in the heat content of all protein aggregates 
present after and before the injection in the sample cell.   
 
Equation 9)    , = − ( − ) 
 
The heat content of a total aggregate any total aggregate population can be defined as 
such: 
 
Equation 10.1)   = ∗  
                10.2)   = ∗  
                10.3)   = ∗   
 
Since the proposed model cites three states in which RXR can exist, there are two 
transitions which contribute to heat change with each injection.  To account for the 
contribuition of each the mole fractions (FD for the dimeric fraction or FT for the tetrameric 
fraction) of each multimer is calculated (See Appendix 1).  These allow the distribution of 
the total number of monomeric units between each state to be quantified.  Since any 
given mole fraction can vary from zero to one, where a zero value means the given 
species is not present to one where the species in question is the only species present, 
we can use the product of each mole fraction with the specific changes in enthalpy to 
quantify the contribution of each transition to the total heat content (See Appendix 2 for 
full derivation). 
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Equation 11.1)   = [ ] , ∗ , + ,  
           11.2)    = [ ] , ∗ , + ,  
                 11.3)   = [ ] , ∗ , + ,  
 
Substituting in equation 10.1-10.3 into equation 8 the heat released after the i-th 
injection can be written as follows: 
 
Equation 12)  , = [ ] , ∗ , + , −
[ ] , ∗ , + , − [ ] , ∗ , + ,  
 
The final step is to incorporate a dilution factor to account for volume lost from the cell 
each injection42: 
 
Equation 13)  , = [ ] , ∗ , + , −
[ ] , ∗ , + , − [ ] , ∗ , + , + 2  
 
This leaves a model system where the dependent variable qi,net exists as a function of 
total monomeric units (MTot,i) with equilibrium constants and changes in enthalpy for each 
injection as parameters.   The equilibrium constants can be determined from the Native-
PAGE assay’s while total protein present (MTot,i) and cell volume V are known (Figure 
11).  Both change in enthalpy values are left as unknowns. The two unknown 
parameters are solved by using non-linear curve fitting analysis.  Initial “guesses” are 
assigned to both enthalpy values and the generated curve is compared to the 
experimental data.  By varying the values through iterative fitting and comparing the fit of 
the theoretical model to experimental data, values are assigned to both parameters. 
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Figure 11. Native PAGE Determination of Equilibrium Constants Native PAGE 
determination of the relative concentrations of the different RXR multimeric states at 
different concentration lvls.  This allows calculation of the different dissociation 
equilibrium 
 
 
Native-PAGE analysis showed that often the levels of RXR monomer present are either 
extremely low or too low for detection by standard staining techniques.  This led to 
questions as to whether the contributions of the monomer form are small enough as to 
be negligible.  If so a simpler equilibrium expression could be used to model the RXR 
tetramer formation.  Therefor as well as the 3 state equilibrium model proposed above a 
simple 2 stage equilibrium model ignoring the contributions of the monomer as negligible 
was investigated.  This equilibrium can be written as follows: 
 
Equation 14)  2[ ] ⇔ [ ]  Equation 15)  = [ ]
[ ]
 
 
The total equivalent monomer concentration after any injection can be written as follows: 
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Equation 16)  [ ] , = 2[ ] + 4
[ ]   
 
The heat released each injection can then be written (see ITC data analysis in Origin, 
2001 for derivation)42: 
 
Equation 17)  , = [ ] , ∗ ( ) − ∆ ([ ] , − [ ] , ) +   
 
Where V is the volume of the sample cell and Δv is the injection volume.  Once again we 
are have a system where qi is a function of [M]T,i.  Using non-linear curve fitting analysis 
along with our Native-PAGE analysis we can assign values to both the dissociation 
constant and change in enthalpy for the dissociation of RXR tetramers into dimers.   
The process of fitting experimental data then involves four parts. First initial guesses 
(often these can be made accurately enough by the Origin fitting software) of each K, 
and ∆H parameter are made. The second is calculations of qi for each injection using the 
initial guesses. This calculated value is compared with the measured heat for the 
corresponding experimental injection.  Third is improvement of the initial parameters by 
the standard Marquardt methods (for a good review of this method see The Levenberg-
Marquardt method for nonlinear least squares curve-fitting problems, Gavin 2013) and 
finally iteration of the above steps until no further significant improvement in the fit 
occurs. 
Non-denaturing Native-PAGE analysis was used to quantify the distribution of the 
different RXR multimer states at different concentrations.   By matching the total protein 
added to specific lanes of a gels to the amount of protein present after a certain number 
of injections in the ITC assay’s a “snapshot” of the multimer distribution after the 
injections in question was obtained.   
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Figure 12. Native-PAGE modeling of mutlmeric states within ITC sample cell.  By 
matching the concentrations of different lanes of the each gel to the known sample cell 
concentration after selected ITC injections, the concentration of each multimer can be 
determined. 
 
Two sets of three Native-Page experiments where performed (see Appendix 4a-b for full 
data).  Each set was paired with a set of partner ITC assays.   Each set of paired PAGE 
and ITC assay’s was performed with the same batch of purified recombinant protein to 
ensure that there was no difference in activity due to differences in protein lots. 
The first set was performed for 15 1.5µL injections of purified RXR protein into a 
sample cell containing only dialyzed sample buffer.  RXR was added to lanes 2-6 in 
concentrations to match the total protein present in the cell after the injections number 2, 
5, 8, 11 and 14 respectively.    
The second set was done with 20 1 µL injections.  By varying our methodology 
with different injections sizes we could ensure that protein aggregation was not 
36 
 
adversely affecting our measurements.  If aggregation is not an issue our values for KD 
and ΔH should be consistent across the 1 µL and 1.5 µL experiments. 
For each Native-P AGE experiment an average Kd for each transition (2 in our first 
model, 1 in the second) was calculated.   For both proposed models heat released per 
injection was defined as a function of total monomeric units injected, = [ ] , .   
Using the non-linear curve fitting analysis built in to the specialized Origin 7.0 software 
provided with the ITC iterative fitting was used to assign values to ΔHD and  ΔHT for 
model one or to ΔHT for the second simpler model.  The fit for each set of calculated 
data to the experimental data set was measured by X 2 analysis.
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS 
 
Ligand Binding Study:  Analysis of the ITC data on the interaction of RXR 
ligand binding domain with agonist and antagonist ligands supports the original 
hypothesis.  It was postulated that the DHA and phytanic acid, being fatty acids able to 
adopt multiple molecular conformations would show a better ability to interact with both 
the "I" and "L" conformations of the RXR ligand binding pocket, while 9cisRA with its 
more rigid retinoid structure would show a preference for the "L" conformation over the 
"I".  Both the wild type and mutant binding assay results support this prediction. 
wt-RXR demonstrated a higher K1 binding affinity than K2 when binding the fatty 
acids.  This may reflect the fact that unbound DHA molecules preferentially bind to 
tetrameric RXR over the dimeric form of the receptor.  This would fit with the literature 
that speculate that the tetrameric form of RXR serves an autorepressive  However, 
9cisRA showed  a lower affinity for K1 to K2 vs DHA.  In these assays as dimeric RXR 
preferentially bound 9cisRA, binding to and dissociating RXR tetramers when the 
dimeric partners where all fully bound already.  Further investigation with both the 
R318A and F315A mutants further supported our hypothesis.  DHA showed similar 
binding to both the R318A and F315A mutants while the decreased binding of 9cisRA to 
the F315A mutant is further evidence that the retinoid has weaker interactions with the 
tetrameric "I" binding pocket.   This is consistent with the growing trend in the literature 
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which shows increased links between DHA and fatty acids to both retinoid and RXR 
requiring heterodimeric partner NRs.33 37, 43  As previously noted there is some evidence 
of cooperativity between binding sites in wt-RXR.   
Of particular interest are the data showing that DHA binds to RXR with a much 
higher affinity than has been suggested from previous gene activation and cell culture 
assay's would have suggested.  Previous studies have shown EC50 and activation 
constants in the low micromolar range for DHA while these data showed that DHA 
physically binds to the receptor with a low nanomolar dissociation constant.  While 
initially this seems like a large discrepancy, when one considers the nature of the RXR 
autorepression mechanism this difference makes sense.  RXR monomers have been 
shown to have the ability to heterodimerize and activate gene expression regardless of 
ligand binding.  Hence, the autorepressive function of the RXR tetramer which 
sequesters the monomer into an oligomeric state where they are transcriptionally active. 
Previous studies have shown that both the presence of a bound ligand and the 
nature of the ligand itself can affect whether a monomer is predisposed to homo- or 
heterodimerize as well as predispose the monomer to certain heterodimeric partners 
over others21 19.  Therefore, it is reasonable that an RXR ligand would bind and 
dissociate the RXR tetramer while only partially activating the homodimerization 
function, leaving a pool of RXR monomers available to heterodimize and activate other 
pathways. 
Looking at the thermodynamics of the ligand binding seen in the assays, two 
trends became noticeable.  Firstly, ΔH values appear to be linked to changes in the 
multimeric state of the receptor.  Binding events which induce no change between dimer, 
tetramer or monomer, such as binding of Danthron to wt-RXR or binding to the R318A 
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mutant, where found to consistently have smaller changes in enthalpy vs. assay’s where 
a change in multimeric state occurs.  In contrast ΔS values are similar across all binding 
events, not matter the dissociation or association events occurring.  We can draw two 
conclusions from this.  Firstly that the protein-protein interactions are largely ΔH driven.  
Also ligand binding by RXR is largely ΔS driven, not surprising given the heavily 
hydrophobic nature of RXR ligand molecules.  
The final thermodynamic observation is between the two fatty acids, DHA and 
phytanic acid.  The major difference between the two is the presence of 4 methyl groups 
on phytanic acid’s main aryl chain while DHA contains none.  This lead to large 
variations in the enthalpy values with phytanic acid between the different  RXR wild type 
and mutant forms than was seen in DHA though both showed similar kinetic  binding 
constants.  Looking at this, the conclusion is drawn that phytanic acid seems to bind in 
an even more ΔS driven manner than DHA due to its bulky structure. 
Tetramer Dissociation Modeling:  In analyzing the RXR dissociation data 
obtained in the absence of ligand two features where looked at beyond goodness of the 
fit as measured by the χ 2 minimization.  For the theoretical dissociation curves 
produced, two features also where noted.  Rate of change for qi vs [M]T,i and any 
inflections point seen are influenced by the values of the equilibrium constants while the 
magnitude  of qi is related to the values of the ΔH components.  By comparing these 
qualities of our fitted models to the experimentally generated curves even for data sets 
which fail to fit we can make observations of how our model differs from our 
experimental data.   The results are as follows: 
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For both models, the monomer-dimer-tetramer and the dimer-tetramer, we failed 
to generate a solution for the assigned parameters which fit to our experimental data.  All 
sets showed a reduced χ2 value reflecting a “good” fit to our experimental data. 
However in comparing the “best fit” , or reduced solutions χ2 generated for the model 
consisting of a monomer-dimer-tetramer equilibrium it was noted that the error in our 
model was associated primarily in the  parameters related to change in enthalpy.  When 
comparing the generated model to the experimental data it was found that the 3 state 
model accurately reflected the experimental data but predicted less heat released for 
each injection than was actually observed (See Figure 11).   
 
 
Figure 13. Partially Fitted Model of 3 State RXR Equilibrium The 3 state model we 
proposed for RXR tetramer dissociation (in yellow) vs our experimental ITC data (blue 
data points) 
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Reviewing the data from initial multimer studies, the data showed that while the 
RXR tetramer dissociation is a multi-stage process it is more exothermic than a simple 
monomer-dimer-tetramer equilibria should be.  The most likely explanation for this would 
be that one of the transitions between multimers features a greater number of sub-units 
dissociating/associating than our original model called for.  In order to expand our model, 
the literature was consulted.  Previous studies (Kersten (2001), Kersten (2004), Zhang 
cite) agree that tetramer’s most likely biological function is to sequester RXR monomers, 
preventing them from being available for homo- and heterodimeric functions.  With the 
biological function in mind, as well as the previous observations from our rejected earlier 
model, it is hypothesized that a more complete model for RXR tetramer dissociation and 
formation would be as follows:   
 
Equation 18)   4[ ] 2[ ] [ ] 4[ ] 
 
The dissociation of the tetramer directly to four monomeric units in this model should 
address the larger energy releases than expected which were observed.  One key 
difference is that since in this model tetramer association and dissociation are one not 
reversible each of these two  transition is defined by a rate constant, k, instead of an 
equilibrium dissociation constant, Kd, as in previous models.  Since to determine the rate 
constants of tetramer dissociation and formation are beyond the scope of our ITC and 
Native-PAGE methodology the equation for  total equivalent monomer concentration 
([M]T,i in terms of each multimeric state as known non-denaturing gel assays can be kept 
in its simplified form.  For this model [M]T,iis defined as follows: 
 
Equation 19)   [ ] , = [ ] + 2[ ] + 4[ ] 
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Determination of rate constants is not possible with our existing ITC methodology as was 
possible for equilibrium constants.  Devising a methodology to determine them is beyond 
the scope of this study.  [M], [D] and [T] can be determined from native-PAGE assays as 
described earlier. 
From here we now look to define our heat release per injection as for the 
previous models.   Again, heat per injection is defined a function of change in total 
equivalent monomer concentration after the injection and before it. 
 
Equation 20)   = [ ] ,  
 
As before the difference in the total heat equivalent for of all contents of the cell before 
and after the injection in question were calculated.  Each heat equivalent is equal to the 
sum of formation of multimer, define as a product of the total monomer concentration, 
the mole fraction of the multimer in question and the change in enthalpy associated with 
that transition as in the original model.  The final equation for heat released per injection, 
qi, is: 
 
Equation 21)  = [ [ ] , + , + , + [ ] , +
, + , ] +  
 
As more subunits are dissociating simultaneously in the tetramer to monomer step of 
this model a greater change in enthalpy per dissociating tetramer is predicted.  This 
should address the failing of the original dissociation model.   This model is currently 
under evaluation as to whether it accurately relects the obtained experimental data. 
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Future Directions:  From here there are several avenues available for future 
exploration.  The first would be the use of full length hRXRα in these studies instead of 
the LBD by itself. This could allow for ITC studies to include binding to short oligo-
nucleotide fragments containing known or suspected RXR REs.   
A second step would be the addition of different nuclear receptors known to 
heterodimerize with RXR. PPAR, LXR and VDR for example have been previously 
shown to have their activity levels modified in mouse models when known RXR agonists 
are administered. 45 46 By including these at different stages of ITC assays it should be 
possible to see an increase or decrease in RXR complex formation depending on the 
ligand or mutant form of RXR used. 
Finally, testing of the final model of RXR tetramer dissociation proposed in this 
dissertation. If the model does fit to the experimental data obtained the next step will be 
elucidation of the rate constants which govern tetramer dissociation to monomers or 
association from dimers. One possible avenue for exploring this would be the use of 
FRET studies and fluorescent tagged RXR-LBD. By using real-time monitoring of 
changes in fluorescence as LBDs associate and dissociate it should be possible to 
measure the rates of tetramer dissociation and association. 
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APPENDIX A   
DERIVATIONS 
 
#1 – Total Equivalent Monomer Concentration 
 [ ] = [ ] + 2[ ] + 4[ ]                                       (eq 1)  
 
#2 -    [ ] ⇔ 2[ ] = [ ]
[ ]
[ ] = [ ]                              (eq 2)  
 
#3 -    [ ] ⇔ 2[ ] = [ ]
[ ]
[ ] = [ ]                                (eq 3)  
 
#4 - [ ] = [ ] + 2[ ] + [ ]                                         substitute (eq 3) into (eq 1) 
 
#5 - [ ] = [ ] + 2 [ ] + [ ]                   substitute (eq 2) into (eq 4) 
 
 
#6 - [ ] = [ ] + [ ] + [ ]                                       simplify 
 
 
 – Mole Fraction of Dimer 
#7 -  = [ ]
[ ] [ ] [ ]
                                                           substitute (eq. 2) (eq. 6)       
#8 - =
[ ]
[ ] [ ]
[ ]                                                     (eq 8) 
 
– Mole Fraction of Tetramer 
#9 -    = [ ]
[ ] [ ] [ ]
                                                        substitute (eq. 3) (eq. 6)       
#10 -  =
[ ]
[ ] [ ]
[ ]                                                 (eq 10) 
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Derivation of the net heat released 
per injection of wt-RXRα in the 
absence of ligand 
 
1. The net heat change per injection is  
the total heat content of multimer 
units contained in the injection 
volume – [the heat content of the  
aggregate multimer forms present 
after each injection - content before 
each injection] (see ITC Data 
Analysis in Origin, MicroCal Inc., 
2004): 
1.1. , = − ( − ) 
2. The heat due to total aggregate 
multimer present, whether before or 
after an injection is defined as (total 
number of RXR monomer units 
present (in moles)) X (enthalpy of 
formation): 
2.1. = ∗  
2.2. = ∗  
2.3. = ∗   
3. Amount of aggregate present (in all 
forms) is equal to (concentration of 
total monomer units) X (sample cell 
volume) 
3.1. = [ ] , ∗  ∗  
3.2. = [ ] , ∗  ∗  
3.3. = [ ] , ∗   ∗   
 
 
 
Parameters 
qi,net Net heat change per injection (cal) 
qi,syr Heat content of aggregates injected (cal) 
 
Heat content of 
aggregates after injection 
(cal) 
 
Heat content of 
aggregates before 
injection (cal) 
 
New Parameters 
 
Number of monomer 
units in cell after 
injection (mol) 
 
Number of monomer 
units in cell before 
injection (mol) 
 
Number of monomer 
units in injected volume 
(mol) 
 Cell volume (L) 
 Injection Volume (L) 
[ ] ,  
Conc. of monomeric 
units after injection  
[ ] ,  
Conc. of monomeric 
units present before 
injection (mol/L) 
[ ] ,  
Conc. of monomeric 
units  
 
 
 
 
 
 
 
 
52 
 
4. Contribution of each transition, 
tetramer to dimer and dimer to 
tetramer, to the net heat content  is 
accounted for by use of the mole 
fraction of each species and each 
transitions  unique change in 
enthalpy 
4.1. = [ ] , ∗ , +
,  
4.2. = [ ] , ∗
, + ,  
4.3. = [ ] , ∗
, + ,  
5. Substitution of 3.1, 3.2 and 3.3 into 
1.1 yields 
5.1. , = [ ] , ∗
, + , −
[ ] , ∗ , +
, − [ ] , ∗
, + ,  
6. Incorporation of a dilution factor for 
volume lost each injection (see ITC 
Data Analysis in Origin, MicroCal 
Inc., 2004 for derivation of term) 
 
 
 
 
 
 
,  
Mole fraction of dimer 
after injection 
,  
Mole fraction of dimer 
before injection 
,  
Mole fraction of dimer 
in inj vol. 
,  
Mole fraction of 
tetramer after 
injection 
,  
Mole fraction of 
tetramer before 
injection 
,  
Mole fraction of 
tetramer in inj vol. 
 
Enthalpy of 
dimer/monomer 
transition (cal/mol) 
 Enthalpy of tetramer/ 
dimer transition 
(cal/mol) 
53 
 
6.1. , = [ ] , ∗ , + , − [ ] , ∗ , +
, − [ ] , ∗ , + , +  
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APPENDIX B   
POOLED STANDARD DEVIATION 
 
Pooled Variance ( ) is defined as: 
1)   = ( ) ( ) ⋯ ( )( ) ( ) ⋯ ( )  
Where n1, n2, ….. nk is the size of each sample set respectively. 
S12, S22, … Sk2 is the variance of each sample set. 
Standard Pooled Deviation ( ) is defined as the square root of the pooled variance: 
2)   =  
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APPENDIX C 
ORIGIN FITTING PROGRAM 
 
[GENERAL INFORMATION] 
Function Name=Tetramer Dissociation 
Brief Description=Dissociation of Tetramer via Dimer to monomer 
Function Source=N/A 
Function Type=User-Defined 
Function Form=Y-Script 
Number Of Parameters=4 
Number Of Independent Variables=3 
Number Of Dependent Variables=1 
Analytical Derivatives for User-Defined=Off 
 
 
[FITTING PARAMETERS] 
Naming Method=User-Defined 
Names=dH_D, dH_T, K_T, K_D 
Meanings=? 
Initial Values=--(V) 
Lower Bounds=--(X,OFF) 
Upper Bounds=--(X,OFF) 
Number Of Significant Digits=3,2 
[FORMULA] 
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NDH=M_(Tot,syr)*dv*(F_(D,syr)* dH_D+F_(T,syr) *dH_T )-M_(Tot,i)*V*(F_(D,i) 
dH_D+F_(T,i) dH_T )-M_(Tot,i-1)*dv(F_(D,i-1) dH_D+F_(T,i-1) dH_T )V+dv/2"  
 
 
[CONSTRAINTS] 
/*Enter general linear constraints here*/ 
 
 
[CONSTANTS] 
 
 
[Parameters Initialization] 
/*Scripts to be executed to initialize parameters.*/ 
 
 
[INITIALIZATIONS] 
/*Scripts to be executed before fitting, a good place for complicated initialization.*/ 
 
 
[AFTER FITTING] 
%W=%H; 
%Z=%H![fit.p].text$; 
%B=%[%Z,@1]; 
%B=%B\r\n%[%Z,@2]; 
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%B=%B\r\nChi^2 = $(nlsf.chisqr,*4); 
%Z=""; 
%Z=%Z\r\n\g(D)H (cal/mole)\t$(nlsf.p1,*4)\t\(177)$(nlsf.e1,*3); 
%Z=%Z\r\nK (mM\)\t$(nlsf.p2,*3)\t\(177)$(nlsf.e2,*2); 
label -s -sa -n fit.p %B%Z; 
SaveRedirection=type.Redirection(16,3); // SDB 1/7/99 REPORT_TO_OUTPUTLOG 
type.BeginResults();  /// RKM 12/10/98 v6.0141 REPORT_TO_OUTPUTLOG 
type -a %B; 
type -a \g(D)H (cal/mole)\t$(nlsf.p1,*4)\t$(nlsf.e1,*3); 
type -a K (mM\)\t$(nlsf.p2,*3)\t$(nlsf.e2,*2); 
type.EndResults(); 
type.Redirection=SaveRedirection; // restore previous redirection. 
delete -v SaveRedirection; 
win -a %W; 
queue {legend;} 
 
 
[ON PARAM CHANGE] 
/*Scripts to be executed when parameters change.*/ 
 
 
[INDEPENDENT VARIABLES] 
xmt= 
xt= 
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injv= 
 
 
[DEPENDENT VARIABLES] 
NDH= 
 
 
[CONTROLS] 
General Linear Constraints=Off 
Initialization Scripts=Off 
Scripts After Fitting=On 
Number Of Duplicates=N/A 
Duplicate Offset=N/A 
Duplicate Unit=N/A 
Generate Curves After Fitting=No 
Curve Point Spacing=Same X as Fitting Data 
Generate Peaks After Fitting=Yes 
Generate Peaks During Fitting=Yes 
Generate Peaks with Baseline=Yes 
Paste Parameters to Plot After Fitting=Yes 
Paste Parameters to Notes Window After Fitting=Yes 
Generate Residuals After Fitting=No 
Keep Parameters=No 
Enable Parameters Initialization=0 
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Compile On Param Change Script=23545 
 
 
[COMPILE FUNCTION] 
Compile=0 
Compile Parameters Initialization=0 
On Param Change Scripts Enabled=0 
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APPENDIX D 
NATIVE PAGE DATA 
 
Definitions : 
[Syr] – RXR-LBD conc. in the ITC syringe 
Δv – Injection Volume (µL) 
V – ITC Sample Cell volume (µL) 
  
1
a 
Inj 
# [M]Total [M]Monomer [M]Dimer [M]Tetramer KD-T KD-D 
  
[Syr] Δv V 
 
2 
8.186E
-08 1.86E-09 
8.40E-
09 1.58E-08 
4.47
E-09 
4.11E-
10 
  
5.55E-
06 1.5 
203
.4 
 
5 
2.046E
-07 2.60E-09 
1.08E-
08 6.50E-08 
1.79
E-09 
6.27E-
10 
     
 
8 
3.274E
-07 2.96E-09 
2.28E-
08 9.23E-08 
5.63
E-09 
3.85E-
10 
     
 
11 
4.502E
-07 1.86E-09 
3.57E-
08 1.47E-07 
8.67
E-09 
9.67E-
11 
     
 
14 
5.73E-
07 1.86E-09 
4.23E-
08 2.64E-07 
6.78
E-09 
8.16E-
11 
     
     
Avg 
5.47
E-09 
3.20E-
10 
     
     
± 
2.57
E-09 
2.31E-
10 
     
             1
b 
Inj 
# [M]Total [M]Monomer [M]Dimer [M]Tetramer KD-T KD-D 
  
[Syr] Δv V 
 
2 
9.484E
-08 3.01E-09 
9.00E-
09 1.64E-08 
4.94
E-09 
1.01E-
09 
  
6.43E-
06 1.5 
203
.4 
 
5 
2.371E
-07 3.49E-09 
1.78E-
08 3.60E-08 
8.79
E-09 
6.84E-
10 
     
 
8 
3.794E
-07 4.66E-09 
2.04E-
08 6.03E-08 
6.92
E-09 
1.06E-
09 
     
 
11 
5.216E
-07 4.12E-09 
2.65E-
08 8.35E-08 
8.44
E-09 
6.38E-
10 
     
 
14 
6.639E
-07 4.80E-09 
2.94E-
08 1.20E-07 
7.24
E-09 
7.84E-
10 
     
     
Avg 7.27 8.36E-
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E-09 10 
     
± 
1.52
E-09 
1.92E-
10 
     
             
             1
c 
Inj 
# [M]Total [M]Monomer [M]Dimer [M]Tetramer KD-T KD-D 
  
[Syr] Δv V 
 
2 
7.271E
-08 
2.90997E-
09 
9.04E-
09 1.48E-08 
5.52
E-09 
9.37E-
10 
  
4.93E-
06 1.5 
203
.4 
 
5 
1.818E
-07 
3.65909E-
09 
1.51E-
08 3.70E-08 
6.18
E-09 
8.85E-
10 
     
 
8 
2.909E
-07 
4.11531E-
09 
1.97E-
08 5.93E-08 
6.53
E-09 
8.61E-
10 
     
 
11 
3.999E
-07 
4.45634E-
09 
2.12E-
08 8.15E-08 
5.53
E-09 
9.35E-
10 
     
 
14 
5.09E-
07 
4.73328E-
09 
2.34E-
08 1.04E-07 
5.27
E-09 
9.58E-
10 
     
     
Avg 
5.81
E-09 
9.15E-
10 
     
     
± 
5.28
E-10 
4.07E-
11 
     
             
             2
a 
Inj 
# [M]Total [M]Monomer [M]Dimer [M]Tetramer KD-T KD-D 
  
[Syr] Δv V 
 
2 
4.848E
-08 
3.22397E-
09 
6.75E-
09 7.57E-09 
6.01
E-09 
1.54E-
09 
  
4.93E-
06 1 
203
.4 
 
6 
1.454E
-07 
4.24298E-
09 
1.00E-
08 2.27E-08 
4.44
E-09 
1.79E-
09 
     
 
10 
2.424E
-07 
4.82096E-
09 
1.13E-
08 3.79E-08 
3.37
E-09 
2.06E-
09 
     
 
14 
3.393E
-07 
5.24404E-
09 
1.46E-
08 5.30E-08 
4.03
E-09 
1.88E-
09 
     
 
18 
4.363E
-07 
5.58408E-
09 
1.86E-
08 6.82E-08 
5.09
E-09 
1.67E-
09 
     
     
Avg 
4.59
E-09 
1.79E-
09 
     
     
± 
1.01
E-09 
1.98E-
10 
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2
b 
Inj 
# [M]Total [M]Monomer [M]Dimer [M]Tetramer KD-T KD-D 
  
[Syr] Δv V 
 
2 
5.516E
-08 
3.22397E-
09 
6.75E-
09 7.57E-09 
6.01
E-09 
1.54E-
09 
  
5.61E-
06 1 
203
.4 
 
6 
1.655E
-07 
4.24298E-
09 
1.00E-
08 2.27E-08 
4.44
E-09 
1.79E-
09 
     
 
10 
2.758E
-07 
4.82096E-
09 
1.13E-
08 3.79E-08 
3.37
E-09 
2.06E-
09 
     
 
14 
3.861E
-07 
5.24404E-
09 
1.46E-
08 5.30E-08 
4.03
E-09 
1.88E-
09 
     
 
18 
4.965E
-07 
5.58408E-
09 
1.86E-
08 6.82E-08 
5.09
E-09 
1.67E-
09 
     
     
Avg 
4.59
E-09 
1.79E-
09 
     
     
± 
1.01
E-09 
1.98E-
10 
     
             
             
             
             2
c 
Inj 
# [M]Total [M]Monomer [M]Dimer [M]Tetramer KD-T KD-D 
  
[Syr] Δv V 
 
2 
7.758E
-08 
2.95773E-
09 
1.36E-
08 1.21E-08 
1.52
E-08 
6.44E-
10 
  
7.89E-
06 1 
203
.4 
 
6 
2.327E
-07 
3.89259E-
09 
2.40E-
08 3.64E-08 
1.59
E-08 
6.30E-
10 
     
 
10 
3.879E
-07 
4.42284E-
09 
2.84E-
08 6.06E-08 
1.33
E-08 
6.88E-
10 
     
 
14 
5.431E
-07 
4.81098E-
09 
3.45E-
08 8.49E-08 
1.41
E-08 
6.70E-
10 
     
 
18 
6.982E
-07 
5.12294E-
09 
3.99E-
08 1.09E-07 
1.46
E-08 
6.58E-
10 
     
     
Avg 
1.46
E-08 
6.58E-
10 
     
     
± 
9.92
E-10 
2.24E-
11 
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APPENDIX E 
 ITC THERMOGRAMS 
 
a) wtRXR with DHA 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
-2
0
Data: wtRXRtoDHA_NDH
Model: TwoSites
Chi^2 = 2433
N1 0.473 ±0.00428 Sites
K1 6.38E8 ±2.53E8 M-1
H1 -3823 ±36.5 cal/mol
S1 27.6 cal/mol/deg
N2 0.666 ±0.0149 Sites
K2 1.49E6 ±4.96E5 M-1
H2 -1348 ±53.9 cal/mol
S2 23.8 cal/mol/deg
 wtRXRtoDHA_NDH
 wtRXRtoDHA_Fit
Molar Ratio
kc
al
/m
ol
e 
of
 in
je
ct
an
t
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0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
-2
0
Data: wtRXRtoDHA_NDH
Model: TwoSites
Chi^2 = 1492
N1 0.483 ±0.00329 Sites
K1 3.71E8 ±1.10E8 M-1
H1 -3796 ±28.3 cal/mol
S1 26.6 cal/mol/deg
N2 0.731 ±0.0171 Sites
K2 5.26E5 ±1.14E5 M-1
H2 -1394 ±56.8 cal/mol
S2 21.5 cal/mol/deg
 wtRXRtoDHA_NDH
 wtRXRtoDHA_Fit
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Data: wtRXRtoDHA_NDH
Model: TwoSites
Chi^2 = 2545
N1 0.507 ±0.00626 Sites
K1 1.20E8 ±4.24E7 M-1
H1 -4028 ±40.1 cal/mol
S1 23.6 cal/mol/deg
N2 0.543 ±0.0175 Sites
K2 6.72E5 ±2.09E5 M-1
H2 -1546 ±108 cal/mol
S2 21.5 cal/mol/deg
 wtRXRtoDHA_NDH
 wtRXRtoDHA_Fit
Molar Ratio
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b) R318A-RXR with DHA 
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Data: R318AtoDHA_NDH
Model: OneSites
Chi^2/DoF = 1039
N 1.543 ±0.00720 Sites
K 4.86E5 ±6.87E4 M-1
H -1980 ±32.08 cal/mol
S 19.4 (cal/mol)/deg
 R318AtoDHA_NDH
 R318AtoDHA_Fit
Molar Ratio
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c) F315A-RXR with DHA 
0.0 0.5 1.0 1.5 2.0 2.5
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Data: F315AtoDHA_NDH
Model: OneSites
Chî 2/DoF = 5466
N 0.843 ±0.00892 Sites
K 4.06E6 ±8.87E5 M-1
H -2440 ±38.74 cal/mol
S 22.1 (cal/mol)/deg
 F315AtoDHA_NDH
 F315AtoDHA_Fit
Molar Ratio
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-2
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0 Data: F315AtoDHA_NDH
Model: OneSites
Chî 2/DoF = 2428
N 0.848 ±0.00546 Sites
K 5.73E6 ±8.97E5 M-1
H -2429 ±24.82 cal/mol
S 22.9 (cal/mol)/deg
 F315AtoDHA_NDH
 F315AtoDHA_Fit
Molar Ratio
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d) wtRXR with 9cisRA 
0.0 0.5 1.0 1.5 2.0 2.5
-2
0
Data: wtto9cisRA_NDH
Model: TwoSites
Chi^2 = 5556
N1 0.798 ±0.0629 Sites
K1 7.05E5 ±9.44E5 M-1
H1 -2474 ±46.1 cal/mol
S1 27.7 cal/mol/deg
N2 0.534 ±0.0400 Sites
K2 5.38E7 ±2.21E7 M-1
H2 -1906 ±294 cal/mol
S2 19.9 cal/mol/deg
 wtto9cisRA_NDH
 wtto9cisRA_Fit
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Data: wtto9cisRA_NDH
Model: TwoSites
Chî 2 = 9784
N1 0.636 ±0.102 Sites
K1 6.89E5±2.73E6 M-1
H1 -2716 ±58.6 cal/mol
S1 26.8 cal/mol/deg
N2 0.638 ±0.0588 Sites
K2 1.26E7 ±4.64E6 M-1
H2 -2785 ±518 cal/mol
S2 14.1 cal/mol/deg
 wtto9cisRA_NDH
 wtto9cisRA_Fit
Molar Ratio
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Data: wtto9cisRA_NDH
Model: TwoSites
Chî 2 = 6218
N1 0.435 ±3.01 Sites
K1 7.97E6 ±1.86E7 M-1
H1 -3534 ±1.30E5 cal/mol
S1 15.3 cal/mol/deg
N2 0.777 ±3.06 Sites
K2 6.16E7 ±6.39E6 M-1
H2 -1964 ±7.22E4 cal/mol
S2 20.0 cal/mol/deg
 wtto9cisRA_NDH
 wtto9cisRA_Fit
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e) R318A-RXR with 9cisRA 
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Data: R318Ato9ci_NDH
Model: OneSites
Chi^2/DoF = 1744
N 0.921 ±0.0230 Sites
K 2.44E5 ±3.38E4 M-1
H -2589 ±52.04 cal/mol
S 16.1 (cal/mol)/deg
 R318Ato9ci_NDH
 R318Ato9ci_Fit
Molar Ratio
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Data: R318Ato9ci_NDH
Model: OneSites
Chi^2/DoF = 3172
N 1.01 ±0.0435 Sites
K 1.50E5 ±2.74E4 M-1
H -2864 ±79.18 cal/mol
S 14.2 (cal/mol)/deg
 R318Ato9ci_NDH
 R318Ato9ci_Fit
Molar Ratio
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Data: R318Ato9ci_NDH
Model: OneSites
Chi^2/DoF = 1855
N 1.24 ±0.0446 Sites
K 1.35E5 ±1.88E4 M-1
H -2716 ±56.63 cal/mol
S 14.4 (cal/mol)/deg
 R318Ato9ci_NDH
 R318Ato9ci_Fit
Molar Ratio
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f) F315A-RXR with 9cisRA 
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0 Data: F315Ato9ci_NDHModel: OneSites
Chi^2/DoF = 4982
N 0.528 ±0.00536 Sites
K 1.37E6 ±1.76E5 M-1
H -6037 ±77.36 cal/mol
S 8.02 (cal/mol)/deg
 F315Ato9ci_NDH
 F315Ato9ci_Fit
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Data: F315Ato9ci_NDH
Model: OneSites
Chi^2/DoF = 1.068E4
N 0.511 ±0.00636 Sites
K 2.78E6 ±6.07E5 M-1
H -5849 ±103.0 cal/mol
S 10.1 (cal/mol)/deg
 F315Ato9ci_NDH
 F315Ato9ci_Fit
Molar Ratio
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Data: F315Ato9ci_NDH
Model: OneSites
Chi^2/DoF = 9555
N 0.526 ±0.00769 Sites
K 1.51E6 ±2.93E5 M-1
H -5621 ±105.5 cal/mol
S 9.60 (cal/mol)/deg
 F315Ato9ci_NDH
 F315Ato9ci_Fit
Molar Ratio
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g) wtRXR with Phytanic Acid 
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0 Data: wtRXRtoPhA_NDH
Model: TwoSites
Chi^2 = 3337
N1 1.187 ±0.00321 Sites
K1 7.58E8 ±1.60E8 M-1
H1 -7393 ±46.9 cal/mol
S1 16.1 cal/mol/deg
N2 2.446 ±0.00961 Sites
K2 3.39E6 ±6.24E5 M-1
H2 -2584 ±61.6 cal/mol
S2 21.3 cal/mol/deg
 wtRXRtoPhA_NDH
 wtRXRtoPhA_Fit
Molar Ratio
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0 Data: wtRXRtoPhA_NDH
Model: TwoSites
Chi^2 = 2240
N1 1.084 ±0.00342 Sites
K1 2.70E8 ±4.57E7 M-1
H1 -7136 ±41.3 cal/mol
S1 14.9 cal/mol/deg
N2 2.100 ±0.00858 Sites
K2 1.66E6 ±2.29E5 M-1
H2 -2877 ±72.5 cal/mol
S2 18.9 cal/mol/deg
 wtRXRtoPhA_NDH
 wtRXRtoPhA_Fit
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Data: wtRXRtoPhA_NDH
Model: TwoSites
Chi^2 = 3148
N1 1.088 ±0.00232 Sites
K1 1.19E9 ±2.68E8 M-1
H1 -7444 ±38.5 cal/mol
S1 16.8 cal/mol/deg
N2 2.333 ±0.0103 Sites
K2 1.49E6 ±2.19E5 M-1
H2 -2889 ±64.2 cal/mol
S2 18.6 cal/mol/deg
 wtRXRtoPhA_NDH
 wtRXRtoPhA_Fit
Molar Ratio
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h) R318A-RXR with Phytanic Acid 
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0
Data: R318AtoPhA_NDH
Model: OneSites
Chi^2/DoF = 1388
N 0.875 ±0.0104 Sites
K 1.09E6 ±1.46E5 M-1
H -1631 ±23.49 cal/mol
S 22.2 (cal/mol)/deg
 R318AtoPhA_NDH
 R318AtoPhA_Fit
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Data: R318AtoPhA_NDH
Model: OneSites
Chî 2/DoF = 832.9
N 0.853 ±0.00626 Sites
K 1.09E6 ±9.12E4 M-1
H -2065 ±18.44 cal/mol
S 20.8 (cal/mol)/deg
 R318AtoPhA_NDH
 R318AtoPhA_Fit
Molar Ratio
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Data: R318AtoPhA_NDH
Model: OneSites
Chi^2/DoF = 4304
N 0.799 ±0.00957 Sites
K 4.72E6 ±1.25E6 M-1
H -1887 ±34.78 cal/mol
S 24.3 (cal/mol)/deg
 R318AtoPhA_NDH
 R318AtoPhA_Fit
Molar Ratio
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i) F315A-RXR with Phytanic Acid 
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Data: F315AtoPhA_NDH
Model: OneSites
Chî 2/DoF = 7889
N 0.856 ±0.0116 Sites
K 3.98E6 ±1.11E6 M-1
H -2275 ±46.31 cal/mol
S 22.6 (cal/mol)/deg
 F315AtoPhA_NDH
 F315AtoPhA_Fit
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Data: F315AtoPhA_NDH
Model: OneSites
Chî 2/DoF = 2071
N 0.931 ±0.00522 Sites
K 2.65E7 ±7.05E6 M-1
H -1853 ±19.56 cal/mol
S 27.8 (cal/mol)/deg
 F315AtoPhA_NDH
 F315AtoPhA_Fit
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Data: F315AtoPhA_NDH
Model: OneSites
Chi^2/DoF = 1277
N 0.875 ±0.00426 Sites
K 9.41E6 ±1.45E6 M-1
H -2024 ±17.01 cal/mol
S 25.2 (cal/mol)/deg
 F315AtoPhA_NDH
 F315AtoPhA_Fit
Molar Ratio
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j) wtRXR with Dantron 
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Data: wttoDant03_NDH
Model: OneSites
Chi^2/DoF = 3421
N 1.21 ±0.0538 Sites
K 1.51E5 ±2.80E4 M-1
H -2717 ±75.04 cal/mol
S 14.7 (cal/mol)/deg
 wttoDant03_NDH
 wttoDant03_Fit
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Data: wttoDant01_NDH
Model: OneSites
Chî 2/DoF = 3452
N 1.01 ±0.0453 Sites
K 1.51E5 ±2.89E4 M-1
H -2862 ±83.11 cal/mol
S 14.2 (cal/mol)/deg
 wttoDant01_NDH
 wttoDant01_Fit
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Data: wttoDant02_NDH
Model: OneSites
Chi^2/DoF = 3009
N 0.960 ±0.0254 Sites
K 1.91E5 ±2.73E4 M-1
H -2985 ±66.15 cal/mol
S 14.2 (cal/mol)/deg
 wttoDant02_NDH
 wttoDant02_Fit
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k) R318A-RXR with Dantron 
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Data: R318AtoDan_NDH
Model: OneSites
Chi^2/DoF = 1321
N 1.32 ±0.0190 Sites
K 1.31E5 ±1.02E4 M-1
H -2689 ±31.02 cal/mol
S 14.5 (cal/mol)/deg
 R318AtoDan_NDH
 R318AtoDan_Fit
Molar Ratio
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Data: R318AtoDan_NDH
Model: OneSites
Chî 2/DoF = 8267
N 1.38 ±0.0574 Sites
K 1.13E5 ±2.35E4 M-1
H -2562 ±80.27 cal/mol
S 14.6 (cal/mol)/deg
 R318AtoDan_NDH
 R318AtoDan_Fit
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Data: R318AtoDan_NDH
Model: OneSites
Chi^2/DoF = 1420
N 1.44 ±0.0266 Sites
K 1.07E5 ±9.51E3 M-1
H -2456 ±33.04 cal/mol
S 14.9 (cal/mol)/deg
 R318AtoDan_NDH
 R318AtoDan_Fit
Molar Ratio
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l) F315A-RXR with Dantron 
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Data: F315AtoDan_NDH
Model: OneSites
Chi^2/DoF = 3458
N 1.30 ±0.148 Sites
K 2.95E4 ±9.28E3 M-1
H -2648 ±133.5 cal/mol
S 11.7 (cal/mol)/deg
 F315AtoDan_NDH
 F315AtoDan_Fit
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Data: F315AtoDan_NDH
Model: OneSites
Chî 2/DoF = 3617
N 1.23 ±0.110 Sites
K 3.43E4 ±9.19E3 M-1
H -2907 ±127.3 cal/mol
S 11.1 (cal/mol)/deg
 F315AtoDan_NDH
 F315AtoDan_Fit
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Data: F315AtoDan_NDH
Model: OneSites
Chi^2/DoF = 817.0
N 1.34 ±0.128 Sites
K 1.73E4 ±3.61E3 M-1
H -3504 ±113.4 cal/mol
S 7.75 (cal/mol)/deg
 F315AtoDan_NDH
 F315AtoDan_Fit
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